ANALISIS HUBUNGAN PENGGUNAAN OBAT FDC/KOMBIPAK PADA PENDERITA YANG DI DIAGNOSIS TB PARU BERDASARKAN KARAKTERISTIK
Suharmiati, Suharmiati; Peneliti pada Pusat Humaniora, Kebijakan Kesehatan dan Pemberdayaan Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Rl, Surabaya
Maryani, Herti; Peneliti pada Pusat Humaniora, Kebijakan Kesehatan dan Pemberdayaan Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Rl, Surabaya
MetadataShow full item record
AbstractBackground: Tuberculosis was an infectious disease and remains a public health problem in the world, including Indonesia. Based on the WHO report in 2009, Indonesia was included into the group of high-burden countries, ranks third after India and China. Indonesia in 1993/1994 began using alloys Anti Tuberculosis (TB) called Kombipak. Although this alloy has a high effectiveness in the treatment of pulmonary TB smear positive but low recovery rates for allegedly due to low adherence to medical treatment regularly and the number of drugs taken too much. Therefore created a new drug which has basically the same alloy with Kombipak/the FOG (Fixed Dose Combination) which can reduce the risk of compliance in treatment and Multi Drug Resistance. Due to the TB treatment. Methods: this study analyzed the use of drugs Kombipak/FDC in patients diagnosed with pulmonary tuberculosis based on the characteristics. This research is a secondary data analysis of Health Survey Research Association (Riskesdas) in 2010 in the form of a structured questionnaire is a questionnaire for households and a questionnaire to individuals aged 15 years and over. Data analyzed by univariate and bivariate analysis using chi square and biner logistic regression. Results: This study found 1278 TB patients who TB diagnosis in the past 12 months from total sample of 177.926 people. The results showed pulmonary tuberculosis patients who get Kombipak/FDC was 83, 1% and most of the respondents treated in the health centers. TB patient who got treatment completed for 6 months or more was 55,8% and mostly treated in government hospitals or health centers. The results showed that low education TB patients had a tendency to use kombipak/FDC for > 6 months 0.659 times compared to those having higher education (p < 0.05). In conclusion, there was a significant correlation between the use Kombipak/FDC for > 6 months with the education level of respondents. It is suggested the active roleof health provider should educate TB patients who were low education patients. Key words: tuberculosis, Kombipak/FDC drugs, health facilities, characteristics
Showing items related by title, author, creator and subject.